目的:判断布地奈德+氨溴索对新生儿肺炎的疗效.方法:新生儿肺炎者符合入组标准的有88例,均在2020年2月-2021年2月行院内治疗,有44例命名为单一组,另44例命名为综合组,布地奈德在前组治疗中使用,布地奈德+氨溴索在后组治疗中使用,观察疗效.结果:治疗前新生儿IL-6、IL-10组间差异在综合组、单一组不明显,P＞0.05.治疗后新生儿IL-6、IL-10组间差异在综合组、单一组较明显,综合组IL-6、IL-10更低,P＜0.05.治疗前新生儿潮气量、呼吸峰流速组间差异在综合组、单一组不明显,P＞0“,”Objective: To evaluate the efficacy of budesonide + ambroxol in the treatment of neonatal pneumonia. Methods: There were 88 cases of neonatal pneumonia patients who met the inclusion criteria and received in-hospital treatment from February 2020 to February 2021. 44 cases were named as single group and 44 cases as comprehensive group. Budesonide was used in the former group and budesonide + ambroxol was used in the latter group, and the efficacy was observed. Results: Before treatment, there was no significant difference between the neonatal IL-6 and IL-10 groups in the comprehensive group and the single group (P BBB 0 0.05). After treatment, the differences between neonatal IL-6 and IL-10 groups were more obvious in the comprehensive group and the single group, and the levels of IL-6 and IL-10 in the comprehensive group were lower (P＜0.05). Before treatment, there were no significant differences in tidal volume and peak respiratory velocity between the integrated group and the single group (P BBB 0 0.05). After treatment, the differences of tidal volume and peak respiratory velocity among groups were more obvious in the integrated group and the single group, and the tidal volume and peak respiratory velocity in the integrated group were better (P＜0.05). The effective rate of neonatal pneumonia in the comprehensive group (97.73％) was higher than that in the single group (81.82％), P＜0.05. Conclusion: Budesonide + Ambroxol has good effect, can reduce the inflammatory response of neonatal pneumonia, let the neonatal lung function recover.